Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
LONDON -- Businesswire -- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s oncology pipeline into the clinic.
“Uz brings extensive clinical experience to Prokarium’s team having spent more than two decades in oncology drug development and research,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to welcome Uz onboard as we expand our clinical portfolio into oncology, and I look forward to working together on the development of our next generation immuno-oncology pipeline.”
“Prokarium’s unique technology based on live, attenuated bacteria is a promising and powerful strategy for reprogramming the tumor microenvironment and eliciting long-lasting anti-tumor effects,” said Dr. Stammberger. “I am excited to exploit the full therapeutic capabilities of our proprietary bacteria in both the monotherapy and combination settings, with our lead program targeting bladder cancer, an indication in which there remains a significant unmet medical need for patients.”
Dr. Stammberger joins Prokarium from the Novartis Institutes for BioMedical Research, where he oversaw the MAPK assets in Translational Clinical Oncology and generated several PoCs/PoMs in different genetically defined solid tumors. Prior to his role at Novartis, Dr. Stammberger was a Clinical Lead at Merck KGaA, responsible for Tepotinib, a small molecule inhibitor of c-Met which is approved in the US and Japan for MetEx14 skip mutant NSCLC. Earlier in his career, he held various positions at Roche and Boehringer Ingelheim. Dr. Stammberger received his Doctor of Medicine as well as the Venia docendi (Adj. Professor of General Thoracic Surgery) from the University of Bern and is a board-certified GP and surgeon.
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London, UK. For further information, visit https://www.prokarium.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005044/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Prokarium
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 기아 ‘더 기아 EV3’ 세계 최초 공개 - 뉴스와이어
- ‘2024 신혼가전도 AI가 대세’ 삼성스토어, 신혼부부 절반은 AI 가전 선택 - 뉴스와이어
- 제주 포도호텔, 더운 여름 맞이 시원한 7만원대 애플망고빙수 출시 - 뉴스와이어
- 신한카드, 국내 여전사 중 브랜드 가치 1위 선정 - 뉴스와이어
- 좋은땅출판사 ‘최저임금 딜레마’ 출간 - 뉴스와이어
- 정관장 사푼사푼, 여름 앞두고 ‘블루스무디 및 에이드’ 2종 출시 - 뉴스와이어
- 서울대 공대 남기태 교수·권민상 교수·KIST 이웅 박사 공동 연구팀, 배터리와 플라스틱 생산에
- 도시바, 전력 반도체를 위한 새로운 300밀리미터 웨이퍼 팹 시설 완공 - 뉴스와이어
- 콘진원-넷플릭스, 방송영상콘텐츠 전문인력 양성을 위한 프로덕션 아카데미 연간 프로그램 운영
- 아태이론물리센터, 2023년 복권기금사업 성과평가 ‘우수’ 획득 - 뉴스와이어